nature portfolio

Corresponding author(s):	Gregor Hagelueken
Last updated by author(s):	Jun 22, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

\sim			
St	at	ist	יורי

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	$oxed{oxed}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🔀 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\times	A description of all covariates tested
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	\square Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
So:	ftware and code

Policy information about <u>availability of computer code</u>

The cryoEM dataset was collected at the IGBMC in Strassbourg using a Krios Titan microscope from ThermoFisher Data collection

Data analysis

The cryoEM dataset was processed with cryoSPARC (3.3.1), RELION (3.1) and phenix (1.20-4444). csparc2star.py was used to migrate data from cryoSPARC to RELION (https://doi.org/10.5281/zenodo.3576630). Alphafold2 (https://github.com/deepmind/alphafold) was used for the structural predictions. Coot (0.9.6) and ChimeraX (1.3) were used for structural modelling. Fiji (1.52p) was used for image analysis.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The coordinate and map data generated in this study have been deposited in the PDB and EMDB databases under accession code 7QE5 [http://doi.org/] and EMD-13930 [http://doi.org/]. The movie data generated in this study are provided in the Supplementary Information. Data underlying all plots are provided as Source data. Source data are provided with this paper.

The coordinate data used in this study are available in the PDB database under accession codes 5UL9 [http://doi.org/10.2210/pdb5UL9/pdb] 2CEY [http://doi.org/10.2210/pdb2CEY/pdb]

5NVA [http://doi.org 2HZL [http://doi.org	/10.2210/pdb3B50/pdb] /10.2210/pdb5NVA/pdb] /10.2210/pdb2HZL/pdb] /10.2210/pdb2ZZV/pdb])
ield-spe	ecific reporting
lease select the o	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences
or a reference copy of	the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>
ife scier.	nces study design
ll studies must dis	sclose on these points even when the disclosure is negative.
Sample size	No sample size calculation was performed. Biochemical experiments were performed in triplicate. Exceptions are the VHH SPR experiments, since they were only needed to select the strongest binding VHHs for downstream experiments. The binding of the VHHs was independently supported by the in vivo experiments, the cryo-EM structure and the competition experiment between VHHQM3 and HiSiaP.
Data exclusions	No data was excluded.
Replication	The ITC binding experiments, the in vivo experiments and microscopy experiments were performed in triplicate. Four SPR experiments were performed to study the interaction of the P- and QM-domains. The replication was successful.
Randomization	Randomization was not performed since it is not applicable to this type of study.
Blinding	Blinding was not performed, since it is not applicable to this type of study.
e require informati	g for specific materials, systems and methods on from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, ted is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
	perimental systems Methods
/a Involved in th	
Antibodies Antibodies	
_	ogy and archaeology MRI-based neuroimaging
	d other organisms
Human res	search participants
Clinical da	za
Dual use re	esearch of concern
.1	
ntibodies	
Antibodies used	6x-His Tag Monoclonal Antibody (4E3D10H2/E3) from Invitrogen (1:1000 dilution). A well established standard Antibody. For detection: m-lgGk BP-HRP from Santa Cruz (sc-516102) (1:5000 dilution).
Validation	The 6xHis antibody was purchased from ThermoFisher (Catalog # MA1-135): https://www.thermofisher.com/order/genome-database/dataSheetPdf? producttype=antibody&productsubtype=antibody_primary&productld=MA1-135&version=233
	The m-IgGk BP-HRP for detection was purchased from SantaCruz. https://www.scbt.com/p/m-igg-kappa-bp-hrp
<u>inimals</u> and	other organisms
alicuinformation	about studies involving animals: ARRIVE guidelines recommended for reporting animal research

Laboratory animals

Male alpacas (Vicugna pacos) were used for the generation of VHHs used in this study.

Wild animals	not applicable
Field-collected samples	not applicable
Ethics oversight	All immunizations were authorized by the Landesuntersuchungsamt Rheinland-Pfalz (23 177-07/A 17-20-005 HP)

Note that full information on the approval of the study protocol must also be provided in the manuscript.